Abstract
Gliomas of astrocytic origin show only a limited chemotherapy response. Chemoresistance is most pronounced in glioblastoma multiforme, the most common and most malignant glioma, with median survival times not much longer than one year. Failure of chemotherapy partly relies on protective mechanisms against the commonly used DNA alkylating agents, but also on the constitutive activation of the pro-survival PI3K-Akt pathway in glioma cells, which inhibits apoptosis. Therefore, new drugs with an alternative mechanism, independent of DNA alkylation, are required. The microtubule targeting drug 2-methoxyestradiol (2-ME) efficiently induces mitotic arrest, apoptosis, but also autophagic cell death in glioma cells in vitro. Moreover, it may be able to inhibit vascularization of the highly vascular gliobastomas, because the drug influences blood vessel sprouting via a HIF-1-dependent mechanism. Although high doses of i.p. injected 2-ME were recently shown to be effective in an orthothopic rat glioma model, clinical phase I/II trials revealed low oral bioavailability. One of the most exciting future perspectives will be the currently ongoing development of improved 2-ME analogs. Compounds, sulphamoylated at positions 3 and 17, combine sufficient toxicity against tumor cells with resistance against metabolic degradation and sufficient plasma levels in experimental animals. They were found to be superior in some animal models of tumor growth and vascularization, following oral application.
Keywords: Glioma, glioblastoma multiforme, chemotherapy, vasculature, 2-methoxyestradiol
Anti-Cancer Agents in Medicinal Chemistry
Title: 2-Methoxyestradiol as a Potential Cytostatic Drug in Gliomas?
Volume: 9 Issue: 1
Author(s): E. Kirches and M. Warich-Kirches
Affiliation:
Keywords: Glioma, glioblastoma multiforme, chemotherapy, vasculature, 2-methoxyestradiol
Abstract: Gliomas of astrocytic origin show only a limited chemotherapy response. Chemoresistance is most pronounced in glioblastoma multiforme, the most common and most malignant glioma, with median survival times not much longer than one year. Failure of chemotherapy partly relies on protective mechanisms against the commonly used DNA alkylating agents, but also on the constitutive activation of the pro-survival PI3K-Akt pathway in glioma cells, which inhibits apoptosis. Therefore, new drugs with an alternative mechanism, independent of DNA alkylation, are required. The microtubule targeting drug 2-methoxyestradiol (2-ME) efficiently induces mitotic arrest, apoptosis, but also autophagic cell death in glioma cells in vitro. Moreover, it may be able to inhibit vascularization of the highly vascular gliobastomas, because the drug influences blood vessel sprouting via a HIF-1-dependent mechanism. Although high doses of i.p. injected 2-ME were recently shown to be effective in an orthothopic rat glioma model, clinical phase I/II trials revealed low oral bioavailability. One of the most exciting future perspectives will be the currently ongoing development of improved 2-ME analogs. Compounds, sulphamoylated at positions 3 and 17, combine sufficient toxicity against tumor cells with resistance against metabolic degradation and sufficient plasma levels in experimental animals. They were found to be superior in some animal models of tumor growth and vascularization, following oral application.
Export Options
About this article
Cite this article as:
Kirches E. and Warich-Kirches M., 2-Methoxyestradiol as a Potential Cytostatic Drug in Gliomas?, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (1) . https://dx.doi.org/10.2174/187152009787047725
DOI https://dx.doi.org/10.2174/187152009787047725 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Overview of Recent Patents on Nanoparticles for Drug Delivery Across the Blood Brain Barrier
Recent Patents on Nanomedicine <i>Click</i> Reaction in the Synthesis of Dendrimer Drug-delivery Systems
Current Medicinal Chemistry Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Encountering and Advancing Through Antiangiogenesis Therapy for Gliomas
Current Pharmaceutical Design Role of Hsp70 in Cancer Growth and Survival
Protein & Peptide Letters Natural Polyphenols in the Treatment of Alzheimer’s Disease
Current Drug Targets Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain
Current Nanoscience Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Cancer Stem Cells and Colorectal Cancer: An Overview
Current Topics in Medicinal Chemistry Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design Endothelial Cell Heterogeneity: A Developmental Biologist’s Perspective
Current Angiogenesis (Discontinued) The Cross-talk between Tristetraprolin and Cytokines in Cancer
Anti-Cancer Agents in Medicinal Chemistry Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
Anti-Cancer Agents in Medicinal Chemistry EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Current Drug Discovery Technologies Mitosis-Targeting Natural Products for Cancer Prevention and Therapy
Current Drug Targets Medicinal and Cosmetic Potentials of Sophorolipids
Mini-Reviews in Medicinal Chemistry Polycation-Based Gene Therapy: Current Knowledge and New Perspectives
Current Gene Therapy